CHRS250117P1500
- 0.05
- -0.02-28.57%
Coherus BioSciences Newsroom
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer
Biosimilars Market Industry Trends and Global Forecasts to 2035, Featuring Amgen, BIOCAD, Biocon, Celltrion, Coherus BioSciences, Eli Lilly, Fresenius Kabi, Pfizer, Sandoz and Teva Pharmaceuticals - ResearchAndMarkets.com
TD Cowen Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)
Coherus BioSciences Price Target Raised to $6.00/Share From $4.00 by Baird
Coherus BioSciences Is Maintained at Outperform by Baird
Coherus Biosciences Announces Board Member Resignation
Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Boosted 137% But Its Business Prospects Need A Lift Too
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Coherus BioSciences Analyst Ratings
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
Express News | Coherus BioSciences Shares up 42% on Deal to Divest Biosimilar of Amgen's Neulasta
Sector Update: Health Care Stocks Decline Premarket Tuesday
Sector Update: Health Care
Coherus Biosciences to Sharpen Fcous on Immuno-oncology Portfolio
Coherus: Post-Closing Proceeds to Repay All of $230M Convertible Notes Due April 2026
Coherus BioSciences: Proceeds to Fund Development of LOQTORZI Combination Programs
Express News | Coherus Announces Agreement to Divest Udenyca® Franchise for up to $558 Million to Intas Pharmaceuticals Ltd.
Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 Million to Intas Pharmaceuticals Ltd.